ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Total Current Liabilities
ScinoPharm Taiwan Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Total Current Liabilities
NT$767.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-9%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Total Current Liabilities
NT$2.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Total Current Liabilities
NT$2.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Total Current Liabilities
NT$1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Total Current Liabilities
NT$8.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Total Current Liabilities
NT$1.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
5%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Total Current Liabilities?
Total Current Liabilities
767.7m
TWD
Based on the financial report for Dec 31, 2024, ScinoPharm Taiwan Ltd's Total Current Liabilities amounts to 767.7m TWD.
What is ScinoPharm Taiwan Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-9%
Over the last year, the Total Current Liabilities growth was 5%. The average annual Total Current Liabilities growth rates for ScinoPharm Taiwan Ltd have been 11% over the past three years , 1% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet